Episode Overview

Podcast: Dr. Chapa’s OBGYN Clinical Pearls
Episode: Livi Post-Sex Vaginal Device: Hmmmm
Date: April 9, 2026
Host: Dr. Chapa

In this quick-hit episode, Dr. Chapa reviews and critiques the new FDA-cleared Livy post-intercourse vaginal absorption device. Meant to absorb residual semen after vaginal intercourse, Livy is being marketed as a way to restore vaginal pH, manage post-coital "drip," and—by implication—possibly help with recurrent bacterial vaginosis (BV). Dr. Chapa provides evidence-based context, points out the limitations of current knowledge, and offers practical guidance for clinicians who may field questions about the product from patients or social media.

Key Discussion Points & Insights

1. What is the Livy Device?

• Description: Livy is described as "the first FDA cleared post-intercourse vaginal absorption device"—essentially a polyurethane, tampon-like single-use product to absorb semen after sex.
• Intended Use: Inserted after vaginal sex, left in for 60 seconds to 15 minutes, then removed and discarded.
• Target Audience: Those annoyed by post-coital "drip" and especially patients dealing with recurrent BV (bacterial vaginosis).

2. Is the Concept Evidence-Based?

• Known Data: There’s strong evidence that semen exposure in the vagina alters the vaginal microbiome, increasing the risk for both new and recurrent BV.
  • “There is absolute data that nobody argues with that semen exposure into the vagina alters the vagina microbiome and increases the risk of both occurrence and recurrence of BV. That's a no brainer.” (Dr. Chapa, 02:28)
• What’s Unknown: There is NO data showing that the duration of semen residence in the vagina—i.e., how quickly it's removed—affects BV risk.
  • “What is unknown... is when you... say that residence time in the vagina is an adverse risk factor. We really don't know that. That's an extrapolation.” (Dr. Chapa, 03:03)
• Extrapolation Problem: The foundation is sound (semen = BV risk), but it’s a leap to say removing semen faster helps prevent BV.
  • “As of right now, the data is kind of binary for semen exposure into the vagina. It's either yes or no...” (Dr. Chapa, 03:19)

3. Published Data & Feasibility Study

• Feasibility Study: Only data is a small abstract (n = 184) published in 2025. It looked at whether users felt reduced "drip" and discomfort—not BV recurrence.
  • “Did it do what it said it was going to do? Did you feel less drip, did you feel less uncomfortable after sex... They’re like, ‘yeah, it did what it’s supposed to do.’ But that’s hardly a win for BV recurrence prevention.” (Dr. Chapa, 07:13)
• Marketing vs. Claims: The press release language is cautious: it says Livy “restores natural pH, helping to manage odor, dripping, and discomfort” rather than stating it can prevent BV. (07:03)

4. Historical Context: Douching

• Failed Interventions: Douching after sex — once considered protective — actually increases BV risk and other infections by disrupting the protective vaginal flora.
  • “Douching was, like, supposed to help prevent BV. It did the exact opposite. It increased BV, mainly because you washed out all the protective lactobacilli.” (Dr. Chapa, 08:24)

5. Other Evidence-Based BV Prevention Strategies

• Partner Treatment: Recent ACOG endorsement of treating male partners for recurrent BV prevention.
  • “Remember that ACOG has endorsed partner treatment or treatment of the male partner for recurrent BV prevention.” (Dr. Chapa, 10:33)
• Vaginal Acidification: Modest, moderate evidence for benefit.
• Vaginal Probiotics: Conflicting but possibly beneficial as adjuvant or standalone.

6. Safety & Cautions with Livy

• Device Use:
  • Do not leave Livy inserted for more than 15 minutes—could absorb beneficial fluids.
  • Do not forget to remove it (risk paralleling forgotten tampons and possible complications).
  • “Number one, don’t leave that in for longer than 15 minutes... Number two, don’t forget it in there, because I could just see... like the forgotten tampon.” (Dr. Chapa, 12:11)
• Unknown Long-Term Impact: Possible unintended consequences, such as removing protective secretions.

7. Practical Takeaways & Clinician Guidance

• Be Ready for Patient Questions: Social media buzz means patients may ask.
• Current Stance: If a patient wants to try it for comfort, fine—but there is no evidence to support claims for BV recurrence prevention. Be honest about the limitations.
  • “My answer is going to be, we just don't know. If it makes you feel better after sex and you want to spend whatever it costs to go get this, fine.” (Dr. Chapa, 11:38)

Notable Quotes & Memorable Moments

• On the evidence gap:
  “Is this legit? So we're doing this in a very quick fashion... because, yeah, it's kind of out there.” (Dr. Chapa, 01:54)

• On douching and lessons learned:
  “So douching is terrible. That's a no, no. We know not to do that.” (Dr. Chapa, 09:05)

• On the market future:
  “I don't know if this is going to last on the market, if it's going to be like a multi billion dollar—like a douching company is multi million dollar. We don't know.” (Dr. Chapa, 09:38)

• Final advice:
  “If it makes you feel better after sex and you want to spend whatever it costs to go get this, fine... I wanted to let you know what’s coming out very quickly on the market.” (Dr. Chapa, 11:44)

Timestamps for Important Segments

| Timestamp | Segment Description | |-----------|--------------------------------------------------------------| | 01:31 | Dr. Chapa introduces the episode and Livy device | | 02:28 | Evidence of semen exposure and BV risk | | 03:03 | Limits of current scientific knowledge on residence time | | 07:03 | Review of existing Livy study/press release | | 08:24 | Historical look at douching and BV | | 10:33 | Evidence-based approaches to BV prevention | | 12:11 | Safety cautions for Livy use | | 13:00 | Practical clinician advice and summary |

Episode Summary

Dr. Chapa offers a nuanced, evidence-focused look at the soon-to-launch Livy vaginal device, clarifying that while the theoretical link between semen exposure and BV recurrence is sound, there is no current evidence that removing semen faster alters that risk. The only data on Livy is on subjective comfort, not clinical endpoints. Douching is a well-documented error of the past, and enthusiasm for Livy should be tempered by history and science. Until more is known, clinicians should be ready to give patients balanced, data-driven advice: use Livy for comfort if desired, but do not expect it to prevent BV.